We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
Cap. Flow
-$10.3M
Cap. Flow %
-0.37%
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.7M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$13.3M
5
JNJ icon
Johnson & Johnson
JNJ
+$11.2M

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$23.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$12.8M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
AMGN icon
Amgen
AMGN
+$11.4M
5
AKRX
Akorn Inc
AKRX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Real Estate 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
76
Natera
NTRA
$38.6B
$6.26M 0.22%
485,758
– –
CLVS
77
DELISTED
Clovis Oncology, Inc.
CLVS
$6.21M 0.22%
75,400
-75,400
-50% -$5.98M
MYOV
78
DELISTED
Myovant Sciences Ltd.
MYOV
$6.19M 0.22%
400,000
– –
BHC icon
79
Bausch Health
BHC
$2.25B
$6.09M 0.22%
425,000
-5,000
-1% -$75.6K
TTPH
80
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.88M 0.21%
42,966
-7,250
-14% -$970K
RARX
81
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$5.78M 0.21%
395,818
– –
ESRX
82
DELISTED
Express Scripts Holding Company
ESRX
$5.35M 0.19%
84,500
– –
UHS icon
83
Universal Health Services
UHS
$9.88B
$5.33M 0.19%
48,076
– –
DXCM icon
84
DexCom
DXCM
$28.8B
$5.28M 0.19%
431,600
+93,600
+28% +$1.65M
SNR
85
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$5.2M 0.19%
567,997
– –
FOMX
86
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.16M 0.18%
930,398
– –
UTHR icon
87
United Therapeutics
UTHR
$26.2B
$5.15M 0.18%
43,961
– –
HSIC icon
88
Henry Schein
HSIC
$9.7B
$5.15M 0.18%
+80,070
New +$5.46M
CAH icon
89
Cardinal Health
CAH
$53.2B
$5.13M 0.18%
76,600
– –
SYK icon
90
Stryker
SYK
$133B
$4.47M 0.16%
+31,500
New +$4.52M
VRNA
91
DELISTED
Verona Pharma
VRNA
$4.22M 0.15%
275,000
– –
FOLD
92
DELISTED
Amicus Therapeutics
FOLD
$4.15M 0.15%
275,494
+114,764
+71% +$1.52M
AGN.PRA
93
DELISTED
Allergan plc
AGN.PRA
$3.69M 0.13%
5,000
– –
ARDX icon
94
Ardelyx
ARDX
$1.25B
$3.58M 0.13%
639,370
– –
NVO
95
Novo Nordisk
NVO
$228B
$3.54M 0.13%
147,200
-287,400
-66% -$6.49M
INVA icon
96
Innoviva
INVA
$1.57B
$3.51M 0.13%
248,803
– –
AXDX
97
DELISTED
Accelerate Diagnostics
AXDX
$3.37M 0.12%
15,000
+5,000
+50% +$1.23M
AMRN
98
Amarin Corp
AMRN
$298M
$3.35M 0.12%
+47,815
New +$3.39M
AFMD
99
DELISTED
Affimed
AFMD
$3.16M 0.11%
140,532
– –
PRGO icon
100
Perrigo
PRGO
$1.43B
$3.16M 0.11%
37,300
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
  • Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
  • Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
  • Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
  • Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
  • Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.